Skip to content

SANGUI BIOTECH INTERNATIONAL INC: 10-Q filed 2017-02-22

What SANGUI BIOTECH INTERNATIONAL INC reported in its quarterly report filed 2017-02-22 (fiscal Q2 2017): 23 published measures, 64 facts as tagged in accession 0001551163-17-000020.

This filing

Form
10-Q (quarterly report)
Filed
2017-02-22
Fiscal period
fiscal Q2 2017
Accession
0001551163-17-000020 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SANGUI BIOTECH INTERNATIONAL INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-12-31165,838USD
At 2016-06-30110,419USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-12-31-223,324USD
At 2016-06-30-247,566USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-12-31180,122USD
At 2016-06-3070,074USD
At 2015-12-3188,273USD
At 2015-06-3017,672USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-07-01 to 2016-12-31-218,615USD184
2015-07-01 to 2015-12-31-258,839USD184

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2016-07-01 to 2016-12-31-183,379USD184
2015-07-01 to 2015-12-31-1,925USD184

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2016-10-01 to 2016-12-3125,797USD92
2016-07-01 to 2016-12-3135,508USD184
2015-10-01 to 2015-12-3115,385USD92
2015-07-01 to 2015-12-3126,856USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2016-07-01 to 2016-12-31233,950USD184
2015-07-01 to 2015-12-31232,698USD184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2015-07-01 to 2015-12-316,977USD184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-12-31-36,878,435USD
At 2016-06-30-36,669,318USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-12-31173USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-148,722USD92
2016-07-01 to 2016-12-31-218,615USD184
2015-10-01 to 2015-12-31-141,890USD92
2015-07-01 to 2015-12-31-249,590USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-12-31152,722USD
At 2016-06-30110,419USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-1,053USD92
2016-07-01 to 2016-12-31-2,835USD184
2015-10-01 to 2015-12-31-14,926USD92
2015-07-01 to 2015-12-31-16,327USD184

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-12-31389,162USD
At 2016-06-30357,985USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-10-01 to 2016-12-31174,143USD92
2016-07-01 to 2016-12-31263,465USD184
2015-10-01 to 2015-12-31157,131USD92
2015-07-01 to 2015-12-31276,217USD184

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2016-10-01 to 2016-12-3125,421USD92
2016-07-01 to 2016-12-3134,850USD184
2015-10-01 to 2015-12-3115,241USD92
2015-07-01 to 2015-12-3126,627USD184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-10-01 to 2016-12-313,908USD92
2016-07-01 to 2016-12-318,328USD184
2015-10-01 to 2015-12-311,455USD92
2015-07-01 to 2015-12-3135,507USD184

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-12-314,513,328USD
At 2016-06-304,513,328USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2016-12-31124,912USD
At 2016-06-30122,789USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-149,775USD92
2016-07-01 to 2016-12-31-221,450USD184
2015-10-01 to 2015-12-31-149,738USD92
2015-07-01 to 2015-12-31-258,839USD184

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2016-10-01 to 2016-12-31-149,775USD92
2016-07-01 to 2016-12-31-221,450USD184
2015-10-01 to 2015-12-31-149,738USD92
2015-07-01 to 2015-12-31-258,839USD184

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-10-01 to 2016-12-3140,755USD92
2016-07-01 to 2016-12-3175,947USD184
2015-10-01 to 2015-12-3142,048USD92
2015-07-01 to 2015-12-3184,565USD184

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-07-01 to 2016-12-31-170USD184
2015-07-01 to 2015-12-31-16,860USD184

Inspect the source

Entity
SANGUI BIOTECH INTERNATIONAL INC / CIK 0001104280
Captured
SEC response SHA-256
80929a3d07bdd3be99cfb5858d464edb9844d0e622d958ee5dce9515baeeed6f

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001104280.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))